Podcast: Play in new window | Download
Podcast: Play in new window | Download
Coronavirus Updates #48 and 49 – Listen to the latest data driven perspectives on the pandemic and soon to be endemic COVID world. Vaccines, boosters, prevention and what is happening now are covered.
For the written versions please visit: https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter
Enjoy,
Dr. M
Podcast: Play in new window | Download
Coronavirus Updates #46 and 47 – Listen to the latest data driven perspectives on the pandemic and soon to be endemic COVID world. Vaccines, boosters, prevention and what is happening now are covered. For the written versions please visit: https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter
Best, Dr. M
Podcast: Play in new window | Download
A few people are asking about the need to vaccinate if you have already had COVID natural illness. What is the story here? Hot off of the press from Cell Reports Medicine, we see: “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.” (Cohen et. al. 2021)
Read more for COVID #41……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/988-volume-11-letter-33-coronavirus-update-42
Read more for COVID #42……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/994-coronavirus-update-42
Happy listening
Dr. M
Podcast: Play in new window | Download
Podcast: Play in new window | Download
Podcast: Play in new window | Download
What are the latest data trends with COVID and children? What vaccine related issues have arisen? We answer these questions and more!
Quick hits
1) Sequelae following a moderate to severe COVID infection continue to plague medical systems. In a new study in the British Medical Journal, we see a 14% increased risk of developing new onset clinical conditions.
“14% of adults aged ≤65 who were infected with SARS-CoV-2 (27 074 of 193 113) had at least one new type of clinical sequelae that required medical care after the acute phase of the illness, which was 4.95% higher than in the 2020 comparator group. The risk for specific new sequelae attributable to SARS-Cov-2 infection after the acute phase, including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety, and fatigue, was significantly greater than in the three comparator groups (2020, 2019, and viral lower respiratory tract illness groups).” (Daugherty et. al. 2021)……….
Read More: Link
Enjoy,
Dr. M
Dr. Paul Smolen has been a practicing pediatrician in Charlotte, N.C as well as serving as an Adjunct Associate Professor at the University of North Carolina School of Medicine-Chapel Hill for the past 37 years. To learn more about Dr. Smolen, click here
Our mission is to stimulate and empower parents with interesting conversations about a wide variety of pediatric topics. To read the complete Mission Statement, click here
